Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Formula | C17H17BrN2O5 |
|||
Molecular Weight | 409.23 | CAS No. | 65673-63-4 | |
Solubility (25°C)* | In vitro | DMSO | 82 mg/mL (200.37 mM) | |
Ethanol | 82 mg/mL (200.37 mM) | |||
Water | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
Description | HA14-1 is a non-peptidic ligand of a Bcl-2 surface pocket with IC50 of ~9 μM. | ||
---|---|---|---|
Targets |
|
||
In vitro | HA14-1 is a small molecule and nonpeptidic ligand of a Bcl-2 surface pocket with IC50 of approximately 9 μM. HA14-1 induces the apoptosis of HL-60 cells in a dose-dependent manner via caspase activation. [1] HA14-1 shows cytotoxic effects on HF1A3, HF4.9 and HF28RA follicular lymphoma B cell lines with LC50 of 4.5 μM, 12.6 μM and 8.1 μM respectively. HA14-1 induces apoptosis of HF1A3, HF4.9 and HF28RA cells via caspase and ROS. [2] |
||
In vivo | HA14-1(400 nM) treatment did not have any significant effect on the growth of glioblastoma tumors in immunodeficient mice. But HA14-1 (400 nM) increases the effect of the DNA-damaging agent on glioblastoma growth in vivo. [3] |
Kinase Assay: |
|
---|---|
Cell Assay: |
|
Animal Study: |
|
|
Data from [Cancer Res, 2011, 71(13), 4494-505]
Comparison of putative BH3 mimetics AT-101, HA14-1, sabutoclax and TW-37 with ABT-737 in platelets. [ Platelets, 2020, 10.1080/09537104.2020.1724276] | PubMed: 32079453 |
Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. [ Oncotarget, 2018, 9(24):16701-16717] | PubMed: 29682179 |
Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin. [Baranski Z, et al. Oncotarget, 2015, 6(34):36113-25] | PubMed: 26416351 |
Lack of GCN5 remarkably enhances the resistance against prolonged endoplasmic reticulum stress-induced apoptosis through up-regulation of Bcl-2 gene expression [Kikuchi H, et al. Biochem Biophys Res Commun, 2015, 463(4):870-5] | PubMed: 26086109 |
BH3 Mimetics Demonstrate Differential Activities Dependent Upon the Functional Repertoire of Pro- and Anti-Apoptotic BCL-3 Family Proteins [Renault TT, et al. J Biol Chem, 2014, 289(38):26481-91] | PubMed: 25096574 |
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents [Fan W Cancer Res, 2011, 71(13):4494-505] | PubMed: 21555370 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.